Here, our validation exercises confirm a positive association of plasma 2-Bromo-4-fluoro-5-methylbenzoic acid IGFBP2 and IGFBP4 with stroke risk among postmenopausal women. An association was not confirmed for IGFBP6, which has low abundance in the brain in animal models [36,37]. From Table 6 one sees that baseline IGFBP4 and IGFBP6 have quite similarPrentice et al. Genome Medicine 2013, 5:112 http://genomemedicine.com/content/5/12/Table 6 Pearson correlation (bolded) and 95 CIs for baseline log-transformed proteomic markers and baseline log-transformed variables involved in CHD and stroke pathophysiologyCHD and stroke risk factors Lipids HDL-C -0.16 (-0.27, -0.05) LDL-C -0.04 (-0.15, 0.08) Inflammatory markers CRP -0.04 (-0.15, 0.08) IL-6 0.09 (-0.03, 0.20) MMP-9 0.08 (-0.03, 0.20) Thrombosis and other blood markers Factor VIII 0.21 (0.10, 0.32) Factor 1.2 0.01 (-0.10, 0.13) D-Dimer -0.02 (-0.14, 0.10) vWF 0.13 (0.02, 0.24) Insulin 0.23 (0.12, 0.33) Glucose 0.03 (-0.08, 0.15) WBC 0.01 (-0.10, 0.12) 0.14 (0.00, 0.28) -0.04 (-0.18, 0.10) 0.15 PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/17184506 (0.00, 0.29) 0.22 (0.07, 0.35) -0.03 (-0.17, 0.11) 0.17 (0.02, 0.31) 0.02 (-0.12, 0.17) 0.06 (-0.10, 0.21) -0.02 (-0.18, 0.13) -0.10 (-0.26, 0.06) 0.08 (-0.22, 0.08) -0.01 (-0.16, 0.14) 0.02 (-0.14, 0.17) 0.06 (-0.09, 0.21) -0.02 (-0.16, 0.12) 0.08 (-0.07, 0.22) 0.08 (-0.07, 0.23) 0.36 (0.23, 0.48) 0.19 (0.05, 0.32) 0.24 (0.10, 0.38) 0.02 (-0.12, 0.16) 0.08 (-0.07, 0.22) 0.09 (-0.06, 0.23) 0.11 (-0.04, 0.26) -0.01 (-0.16, 0.13) -0.04 (-0.18, 0.11) -0.44 (-0.55, -0.31) -0.10 (-0.24, 0.04) -0.11 (-0.29, 0.08) 0.06 (-0.13, 0.24) -0.04 (-0.23, 0.15) 0.15 (-0.03, 0.33) 0.02 (-0.16, 0.21) -0.13 (-0.31, 0.07) -0.30 (-0.46, -0.12) 0.23 (0.05, 0.39) -0.02 (-0.20, 0.16) 0.00 (-0.19, 0.18) 0.18 (0.00, 0.35) 0.29 (0.11, 0.44) 0.29 (0.10, 0.45) 0.09 (-0.10, 0.27) 0.19 (0.00, 0.37) 0.06 (-0.13, 0.25) 0.00 (-0.19, 0.20) 0.09 (-0.10, 0.28) 0.23 (0.04, 0.40) 0.28 (0.08, 0.45) 0.21 (0.02, 0.39) 0.12 (-0.06, 0.30) 0.31 (0.14, 0.47) 0.15 (-0.04, 0.32) 0.06 (-0.13, 0.24) 0.04 (-0.14, 0.22) 0.26 (0.07, 0.43) 0.11 (-0.08, 0.29) 0.02 (-0.12, 0.17) 0.30 (0.16, 0.43) 0.30 (0.16, 0.43) 0.12 (-0.03, 0.27) 0.09 (-0.07, 0.24) -0.06 (-0.21, 0.10) -0.04 (-0.18, 0.11) 0.05 (-0.10, 0.20) 0.11 (-0.03, 0.26) 0.05 (-0.10, 0.19) -0.11 (-0.25, 0.04) -0.06 (-0.20, 0.09) -0.11 (-0.28, 0.08) -0.16 (-0.34, 0.03) -0.20 (-0.37, -0.01) -0.02 (-0.21, 0.16) (S)-tert-Butyl 6-(hydroxymethyl)-5-azaspiro[2.4]heptane-5-carboxylate 0.30 (0.12, 0.46) 0.06 (-0.12, 0.24) -0.04 (-0.23, 0.15) 0.21 (0.01, 0.39) 0.09 (-0.11, 0.27) 0.13 (-0.06, 0.30) 0.23 (0.05, 0.40) 0.07 (-0.11, 0.25) -0.23 (-0.36, -0.09) 0.04 (-0.10, 0.19) -0.10 (-0.24, 0.06) 0.09 (-0.06, 0.24) -0.25 (-0.38, -0.11) -0.01 (-0.16, 0.13) 0.22 (0.08, 0.36) -0.05 (-0.19, 0.10) 0.52 (0.37, 0.64) -0.15 (-0.32, 0.04) -0.25 (-0.41, -0.07) 0.01 (-0.18, 0.19) -0.18 (-0.36, 0.01) 0.02 (-0.17, 0.21) -0.21 (-0.38, -0.03) 0.14 (-0.04, 8-Tetrabromopyrene 4-Fluoro-2-(trifluoromethyl)phenol (S)-1-(tetrahydrofuran-2-yl)ethan-1-one Fludioxonil Potassium (((tert-butoxycarbonyl)amino)methyl)trifluoroborate 2-(Trifluoromethyl)isonicotinic acid H-Lys(Boc)-OtBu.HCl 3-Methyl-3 0.32) Proteomic marker B2M ORM1 THBS1 CFD IGFBP1 IGFBP2 IGFBP4 IGFBP6 HPXPage 11 ofPrentice et al. Genome Medicine 2013, 5:112 http://genomemedicine.com/content/5/12/Table 6 Pearson correlation (bolded) and 95 CIs for baseline log-transformed proteomic markers and baseline log-transformed variables involved in CHD and stroke pathophysiology (Continued)Blood pressure Systolic BP 0.08 (-0.04, 0.19) Diastolic BP 0.18 (0.08, 0.28) 0.10 (-0.04, 0.24) 0.08 (-0.06, 0.22) 0.17 (0.02, 0.32) -0.11 (-0.25, 0.05) 0.04 (-0.11, 0.18) 0.19 (0.05, 0.32) -0.03 (-0.17, 0.12) 0.00 (-0.15, 0.14) -0.25 (-0.42, -0.07) -0.06 (-0.21, 0.09).